IE46317B1 - Imidazopyridazines and their use as therapeutic agents - Google Patents
Imidazopyridazines and their use as therapeutic agentsInfo
- Publication number
- IE46317B1 IE46317B1 IE186/78A IE18678A IE46317B1 IE 46317 B1 IE46317 B1 IE 46317B1 IE 186/78 A IE186/78 A IE 186/78A IE 18678 A IE18678 A IE 18678A IE 46317 B1 IE46317 B1 IE 46317B1
- Authority
- IE
- Ireland
- Prior art keywords
- group
- compound
- compounds
- hydrogen
- alkyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 150000005233 imidazopyridazines Chemical class 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 96
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 28
- -1 eunino Chemical group 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 231100000252 nontoxic Toxicity 0.000 claims description 9
- 230000003000 nontoxic effect Effects 0.000 claims description 9
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 150000004892 pyridazines Chemical class 0.000 claims description 4
- 208000009079 Bronchial Spasm Diseases 0.000 claims description 3
- 208000014181 Bronchial disease Diseases 0.000 claims description 3
- 206010006482 Bronchospasm Diseases 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 238000006073 displacement reaction Methods 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
- 150000004703 alkoxides Chemical class 0.000 claims description 2
- 230000029936 alkylation Effects 0.000 claims description 2
- 238000005804 alkylation reaction Methods 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 150000002900 organolithium compounds Chemical class 0.000 claims description 2
- ZOCLAPYLSUCOGI-UHFFFAOYSA-M potassium hydrosulfide Chemical compound [SH-].[K+] ZOCLAPYLSUCOGI-UHFFFAOYSA-M 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 150000003335 secondary amines Chemical class 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 229940125878 compound 36 Drugs 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- AKJQYWFGJWOGKD-UHFFFAOYSA-N imidazo[1,5-b]pyridazine Chemical compound N1=CC=CC2=CN=CN21 AKJQYWFGJWOGKD-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 159
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
- 239000000243 solution Substances 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 239000002904 solvent Substances 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 20
- 239000000047 product Substances 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 125000004494 ethyl ester group Chemical group 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- 235000019341 magnesium sulphate Nutrition 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- WACQKHWOTAEEFS-UHFFFAOYSA-N cyclohexane;ethyl acetate Chemical compound CCOC(C)=O.C1CCCCC1 WACQKHWOTAEEFS-UHFFFAOYSA-N 0.000 description 8
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 8
- 238000001953 recrystallisation Methods 0.000 description 8
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 7
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 239000011976 maleic acid Substances 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- GYJYWHPANKJGGS-UHFFFAOYSA-N 3-methyl-N-[1-(6-oxo-1H-pyridazin-3-yl)ethyl]butanamide Chemical compound C(CC(C)C)(=O)NC(C)C1=NNC(C=C1)=O GYJYWHPANKJGGS-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
- 150000008065 acid anhydrides Chemical class 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- IEJPPSMHUUQABK-UHFFFAOYSA-N 2,4-diphenyl-4h-1,3-oxazol-5-one Chemical compound O=C1OC(C=2C=CC=CC=2)=NC1C1=CC=CC=C1 IEJPPSMHUUQABK-UHFFFAOYSA-N 0.000 description 2
- IITDXGVVBHAMHN-UHFFFAOYSA-N 5-benzamido-4-oxopentanoic acid Chemical compound OC(=O)CCC(=O)CNC(=O)C1=CC=CC=C1 IITDXGVVBHAMHN-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- UFOVABHOFZLITJ-UHFFFAOYSA-N N-[(6-oxo-4,5-dihydro-1H-pyridazin-3-yl)methyl]benzamide Chemical compound C(C1=CC=CC=C1)(=O)NCC1=NNC(CC1)=O UFOVABHOFZLITJ-UHFFFAOYSA-N 0.000 description 2
- WSWXLJOGYKNVPZ-UHFFFAOYSA-N N-[2-methyl-1-(6-oxo-4,5-dihydro-1H-pyridazin-3-yl)propyl]benzamide Chemical compound C(C1=CC=CC=C1)(=O)NC(C(C)C)C1=NNC(CC1)=O WSWXLJOGYKNVPZ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000000538 analytical sample Substances 0.000 description 2
- 229960004977 anhydrous lactose Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000002688 maleic acid derivatives Chemical class 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- NOZGNXJZXAXMRV-UHFFFAOYSA-N n-[(6-oxo-1h-pyridazin-3-yl)methyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NCC=1C=CC(=O)NN=1 NOZGNXJZXAXMRV-UHFFFAOYSA-N 0.000 description 2
- UELVVLPHGCBLEC-UHFFFAOYSA-N n-[1-(6-oxo-1h-pyridazin-3-yl)ethyl]benzamide Chemical compound C1=CC(=O)NN=C1C(C)NC(=O)C1=CC=CC=C1 UELVVLPHGCBLEC-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- BKWQKVJYXODDAC-UHFFFAOYSA-N 1,2-dihydropyridazine Chemical compound N1NC=CC=C1 BKWQKVJYXODDAC-UHFFFAOYSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- DTIMTCJMOWXMGT-UHFFFAOYSA-N 2-(butanoylamino)propanoic acid Chemical compound CCCC(=O)NC(C)C(O)=O DTIMTCJMOWXMGT-UHFFFAOYSA-N 0.000 description 1
- ZPCCKTOTECQSQQ-UHFFFAOYSA-N 2-phenyl-4-propan-2-yl-2H-1,3-oxazol-5-one Chemical compound C(C)(C)C1=NC(OC1=O)C1=CC=CC=C1 ZPCCKTOTECQSQQ-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- QKCKCXFWENOGER-UHFFFAOYSA-N 2-phenyloxazol-5(4H)-one Chemical compound O1C(=O)CN=C1C1=CC=CC=C1 QKCKCXFWENOGER-UHFFFAOYSA-N 0.000 description 1
- RJTUMDYOXHADII-UHFFFAOYSA-N 4-chloro-2-ethyl-4-oxobutanoic acid Chemical compound CCC(C(O)=O)CC(Cl)=O RJTUMDYOXHADII-UHFFFAOYSA-N 0.000 description 1
- MMZMROHDQCJAJT-UHFFFAOYSA-N 4-chloro-4-oxobutanoic acid Chemical compound OC(=O)CCC(Cl)=O MMZMROHDQCJAJT-UHFFFAOYSA-N 0.000 description 1
- HUJYZMNFJYVWDY-UHFFFAOYSA-N 5-(3-methylbutanoylamino)-4-oxohexanoic acid Chemical compound C(CC(C)C)(=O)NC(C(CCC(=O)O)=O)C HUJYZMNFJYVWDY-UHFFFAOYSA-N 0.000 description 1
- KGXJQPATVCYXFL-UHFFFAOYSA-N 5-benzamido-4-oxohexanoic acid Chemical compound OC(=O)CCC(=O)C(C)NC(=O)C1=CC=CC=C1 KGXJQPATVCYXFL-UHFFFAOYSA-N 0.000 description 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 1
- RILNCPBFGQUIFR-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)NC(C(C)C)C1=NNC(C=C1)=O.Cl Chemical compound C(C1=CC=CC=C1)(=O)NC(C(C)C)C1=NNC(C=C1)=O.Cl RILNCPBFGQUIFR-UHFFFAOYSA-N 0.000 description 1
- MUZSIGFGAAREGY-UHFFFAOYSA-N C(CCC)(=O)NC(C(CCC(=O)O)=O)CC Chemical compound C(CCC)(=O)NC(C(CCC(=O)O)=O)CC MUZSIGFGAAREGY-UHFFFAOYSA-N 0.000 description 1
- ZWANSPDKNGXFIE-UHFFFAOYSA-N CCCC(NC(C(C)C)C(C=C1)=NNC1=O)=O Chemical compound CCCC(NC(C(C)C)C(C=C1)=NNC1=O)=O ZWANSPDKNGXFIE-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 238000006021 Dakin-West synthesis reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- PFKXPIPJHXUJCD-UHFFFAOYSA-N N-[(6-oxo-1H-pyridazin-3-yl)methyl]butanamide Chemical compound C(CCC)(=O)NCC1=NNC(C=C1)=O PFKXPIPJHXUJCD-UHFFFAOYSA-N 0.000 description 1
- CXDMQGOLSFWNLG-UHFFFAOYSA-N N-[(6-oxo-4,5-dihydro-1H-pyridazin-3-yl)methyl]butanamide Chemical compound C(CCC)(=O)NCC1=NNC(CC1)=O CXDMQGOLSFWNLG-UHFFFAOYSA-N 0.000 description 1
- ZLBAXNDHVQQMKH-UHFFFAOYSA-N N-[1-(6-oxo-1H-pyridazin-3-yl)ethyl]butanamide Chemical compound CCCC(=O)NC(C)C1=NNC(=O)C=C1 ZLBAXNDHVQQMKH-UHFFFAOYSA-N 0.000 description 1
- YOKBHSGTWFHHBI-UHFFFAOYSA-N N-[1-(6-oxo-1H-pyridazin-3-yl)propyl]butanamide Chemical compound C(CCC)(=O)NC(CC)C1=NNC(C=C1)=O YOKBHSGTWFHHBI-UHFFFAOYSA-N 0.000 description 1
- WMQPKQWYTGPWCN-UHFFFAOYSA-N N-[1-(6-oxo-4,5-dihydro-1H-pyridazin-3-yl)ethyl]benzamide Chemical compound C(C1=CC=CC=C1)(=O)NC(C)C1=NNC(CC1)=O WMQPKQWYTGPWCN-UHFFFAOYSA-N 0.000 description 1
- JBERZDJKVSEWGV-UHFFFAOYSA-N N-[1-(6-oxo-4,5-dihydro-1H-pyridazin-3-yl)propyl]butanamide Chemical compound C(CCC)(=O)NC(CC)C1=NNC(CC1)=O JBERZDJKVSEWGV-UHFFFAOYSA-N 0.000 description 1
- QSBWJJSMZUTJRL-UHFFFAOYSA-N N-[2-methyl-1-(6-oxo-1H-pyridazin-3-yl)propyl]benzamide Chemical compound C(C1=CC=CC=C1)(=O)NC(C(C)C)C1=NNC(C=C1)=O QSBWJJSMZUTJRL-UHFFFAOYSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- OJPSNARFDYTAEN-LURJTMIESA-N N-isovaleryl-L-alanine Chemical compound CC(C)CC(=O)N[C@@H](C)C(O)=O OJPSNARFDYTAEN-LURJTMIESA-N 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 1
- WPSSBBPLVMTKRN-UHFFFAOYSA-N butyrylglycine Chemical compound CCCC(=O)NCC(O)=O WPSSBBPLVMTKRN-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- JCYNNMTVYMVGMV-UHFFFAOYSA-N cyclohexane;ethanol Chemical compound CCO.C1CCCCC1 JCYNNMTVYMVGMV-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- IXZFDJXHLQQSGQ-UHFFFAOYSA-N ethyl 4-chloro-4-oxobutanoate Chemical compound CCOC(=O)CCC(Cl)=O IXZFDJXHLQQSGQ-UHFFFAOYSA-N 0.000 description 1
- KSDDQTRMPYGTHF-UHFFFAOYSA-N ethyl 5-(3-methylbutanoylamino)-4-oxohexanoate Chemical compound C(CC(C)C)(=O)NC(C(CCC(=O)OCC)=O)C KSDDQTRMPYGTHF-UHFFFAOYSA-N 0.000 description 1
- ANFZRGMDGDYNGA-UHFFFAOYSA-N ethyl acetate;propan-2-ol Chemical compound CC(C)O.CCOC(C)=O ANFZRGMDGDYNGA-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 150000004721 gamma keto acids Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910001507 metal halide Inorganic materials 0.000 description 1
- 150000005309 metal halides Chemical class 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910003445 palladium oxide Inorganic materials 0.000 description 1
- JQPTYAILLJKUCY-UHFFFAOYSA-N palladium(ii) oxide Chemical compound [O-2].[Pd+2] JQPTYAILLJKUCY-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007944 soluble tablet Substances 0.000 description 1
- 239000003506 spasmogen Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to 5 -bO-pyridazines.
The compounds according to the present invention correspond to the following formula:
[FR2380281A1]
Description
This invention relates to novel imidazo[l,5-b] pyridazines, to a process for the production thereof, to pharmaceutical preparations containing said pyridazines and to methods of medical treatment employing them.
According to the present invention there are provided imidazo[l,5-b]pyridazines of the general formula' X: R.
(I) '2 and physiologically acceptable non-toxic salts thereof, in which Rj, Rg and R^ which may he the same or different represent a straight or branched chain alkyl or alkenyl group, 0r an aryl or aralkyl group in which the aryl group or the aryl moiety of the aralkyl group may be substituted by one or more hydroxy, alkoxy, or halogen atoms; and in which either or both of Rj and R„ may additionally represent hydrogen atoms; and in which Rj may further represent a halogen atom, preferably chlorine, or an alkoxy, hydroxy, alkylthio or thiol group or may represent a group R^R^N- in which R^ represents a hydrogen atom or an alkyl or alkenyl group and R^ represents a hydrogen, atom or an amino group or an alkyl, alkenyl, aryl or aralkyl group, in which the aryl group or the aryl moiety of the aralkyl group may optionally be substituted with one or more hydroxy or alkoxy groups; and in which the group Rj may also represent an acyl function RgCO-, in which Rg is a hydrogen atom or an alkyl or an aryl group; and in which the groups and R^ may together with the adjacent nitrogen atom form a saturated 4 to 8 membered heterocyclic ring which can contain an additional heteroatom, preferably N, S or 0, and may be substituted (on either a carbon atom or a hetero atom) by for example a methyl group.
Where reference is made herein to alkyl as a group, or part of a group such as aralkyl or alkoxy, this preferably meatis one containing from 1 to 6 carbon atoms, in particular 1 to 4 carbon atoms. References herein to alkenyl preferably mean those groups containing 3 to 6 carbon atoms. Aryl preferably means phenyl and aralkyl preferably means benzyl or phenethyl,.
The compounds of formula I may be isolated as non-toxic physiologically acceptable salts in particular acid addition salts. Examples of such salts include salts with organic acids such as acetic acid, maleic acid and tartaric acid and with inorganic acids such as hydrochloric and sulphuric acid. The processes for the preparation of the compounds of the invention include as an optional step the isolation of the compounds of formula I as non-toxic physiologically acceptable salts.
Preferred novel compounds according to the invention^ are those in which the groups have the meanings given below: R^ is hydrogen; alkyl, preferably methyl, ethyl or n-propyl; halo, preferably chloro; alkoxy, preferably methoxy; hydroxy; or aryl, preferably phenyl; or the group NR^Rg where R^ is hydrogen or alkyl, preferably methyl; and R^ is hydrogen, amino, alkyl, preferably methyl, ethyl or isopropyl; or an acyl function RgCO in which Rg is alkyl, preferably methyl; or NR^R^ is a five or six-membered heterocyclic ring preferably a piperidino ring; R2 is alkyl, preferably propyl or isobutyl; or aryl, preferably phenyl; and R^ is hydrogen or alkyl, preferably methyl, ethyl or isopropyl.
Compounds in which R^ represents hydrogen, alkyl, alkoxy, aryl, or a group -NR^R^ in which R^ is hydrogen or alkyl and R5 is hydrogen, amino, alkyl or RgCO where Rg is alkyl, or NR^Rg represents piperidino are preferred.
Specific preferred compounds according to the invention are those, the preparation of which is described in the Examples Two particularly preferred compounds are :l-methyl-6-methylanlino-3-propylimidazo[1,5-b]pyridazine, 6-ethyl-l-methyl-3-propylimidazo[l,5-b]pyridazine, and their hydrochloride or maleate salts. -425 6 317 Tautomerism may exist in the compounds according to the invention for example when R^ represents a hydroxy, thiol, or primary or secondary amino group. The invention includes within its scope the tautomeric forms of the compounds of formula I.
The compounds of formula I and. non-toxic physiologically acceptable salts thereof have been found to have useful therapeutic activity. Thus they relax smooth muscle with concomitant stimulation of the enzyme adenylate cyclase giving enhanced intracellular levels of cyclic adenosine monophosphate (eAMP). The mechanism does not involve β-adrenoceptors. The compounds also inhibit the enzyme phosphodiesterase. Accordingly the compounds are particularly useful in the treatment of diseases of the lung such as asthma and bronchitis and in the treatment of peripheral vascular disease such as hypertension and Raynaud1s syndrome.
The compounds would also be useful in the treatment of skin diseases such as psoriasis.
The relaxant activity of these compounds on smooth muscle is demonstrated by their action (a) in reducing the tone of isolated guinea-pig tracheal strip preparations (R.F. Cobum & T. Tomita, 1973; Am. J. Physiol., 224. 1072-1080), and (h) in reducing bronchospasm induced by spasmogens such as histamine, 5-hydroxytryptamine and acetylcholine in the -54 6 317 anaesthetized guinea-pig (G.W. Lynn James, 1969; J.
Pharm. Pharmac., 21, 579-386).
The ability of compounds to inhibit the enzyme phosphodiesterase is demonstrated on an enzyme preparation from human lung on the basis of the· method described by T.R. Russell, W.L. Terasaki & M.M. Appleman (1973) J. Biol. Chem. 248, 1334-1340.
The compounds of formula I where R^ represents hydroxy may be prepared by cyclising a 3-substituted-pyridazin-6(lH)one of general formula II: in Tihich R2 and R^ have the meaning given above. Subsequent conversion of the resulting compound of formula I in which R^ is hydroxy into other compounds of the invention may be carried out as described below.
A suitable agent for carrying out the cyclisation reaction on compounds of formula II is a strong acid, for example polyphosphoric acid. The reaction is preferably carried out with heating and optionally in the presence of a suitable solvent. A compound of formula I in which R^ is hydroxy may then be converted into other Compounds according to the invention. For example where R^ is halogen reaction with a compound which -646 317 replaces the hydroxy group hy a halogen atom for example, hy refluxing with a halogen-containing phosphorus compound will yield compounds in which R^ is halogen. Thus, refluxing with phosphorus oxychloride, phosphorus trichloride or phosphorus pentachloride results in a compound of formula I in which R^ is chlorine, and likewise refluxing with phosphorus tribromide gives a compound in which R^ is bromine. In an alternative procedure the compound of formula II may be refluxed optionally in the presence of a solvent for example, ethylene dichloride, with a halogen introducing reagent such as the halogen containing phosphorus compounds recited above to give directly compounds of formula I in which R^ is halogen. This procedure is particularly applicable to the preparation of the chloro compound utilising-phosphorus oxychloride as the halogencontaining phosphorus compound.
Other compounds of general formula 1 may he prepared from the compounds of formula I in which R^ is halogen hy processes described below.
In particular the compound in which R^ is chlorine may he utilised as starting material for these other processes. Such processes may involve a nucleophilic displacement reaction.
For example, the chloro compound may he treated with ammonia or a primary or secondary amine to give compounds of formula I in which R^ is NR^R^; this reaction i,s usually carried out at elevated temperatures, and a solvent such as an alcohol e.g. -746317 ethanol may conveniently he used. This reaction is not suitable for the direct production of compounds in which R^ is RgCO. For the production of these compounds, an acylation step is necessary as described below. For compounds in which R^ (in the group NR^R^) is an amino group, the chloro compound may be refluxed with a hydrazine e.g. hydrazine hydrate in a solvent. An alcohol e.g. ethanol is again a suitable solvent.
For the production of compounds in which Rj is an alkoxy group one may conveniently treat a chloro compound of formula I with an alkoxide, conveniently a solution of an alkali metal alkoxide in the corresponding alcohol. Catalytic hydrogenation of a chloro compound of formula I using for example palladised charcoal as catalyst will give a compound according to the invention in which Rj is hydrogen. This reaction may be carried out in a solvent such as ethyl acetate, in the presence of a base e.g. triethylamine.
Further reactions may be effected to convert one compound according to the invention into another compound of the invention. Thus, for example, where Rj is amino, this group may be acylated with for example an acid anhydride in the presence of the corresponding acid e.g. acetic anhydride in the presence of acetic acid to give compounds in which Rj represents a group -NR^Rj where R^ represents RgCO-, as defined above. Other conventional acylating agents, such as an acid chloride, may also be used. -84 6 317 Compounds in which R^ represents alkyl, in particular methyl, or alkenyl or aryl or aralkyl, which may he substituted as mentioned above may be made by treating a compound of formula X in which Rj is hydrogen with an appropriate organo lithium compound (e.g. an alkyl lithium), conveniently in an ether solvent such as diethyl ether or tetrahydrofuran, to give an appropriately 6-substituted 5,6-dihydro-imidazo[l,5-b]pyridazine, which is subsequently dehydrogenated e.g. by refluxing with palladium oxide/charcoal in p-cymene, or oxidised using a suitable oxidising agent, for example, potassium ferricyanide, to yield the compound of formula I.
Compounds in which R^ is a thiol group may be prepared by treating a compound of formula I in which R^ is chlorine with potassium hydrogen sulphide. Alkylation of the thiol compounds yields compounds of formula I in which R^ is alkylthio.
In addition to the methods of preparation described above, compounds of formula I in which R^ is halogen other than chlorine may be prepared by displacement reactions on the chloro compound using an appropriate metal halide such as sodium bromide or potassium iodide in an aprotic solvent such as acetone or dimethylformamide.
Compounds of formula II above may conveniently be prepared from compounds of formula III, using a suitable oxidising agent for example bromine. -9*46317 NHC0Rn (HI) If desired the acyl group -CORg in a compound of formula II may he replaced hy an alternative acyl group prior to the cyclisation thereof, via the intermediacy of the amino derivative IV and subsequent re-acylation.
Compounds of formula XII, which constitute a further aspect of the invention, may be prepared from compounds of formula V or the corresponding acids VX by reaction with hydrazine. The reaction is carried out in a suitable solvent such as ethanol, without isolation of the intermediate hydrazone.
AlkOOCCHgCHgCOCHNHCORg HOOCCHgCHgCOCHNHCORg (V) (VI) The 3-substituted-pyridazin-6(lH)-ones XI and 3-substituted-4,5dihydro-pyridazin-6(lH)-ones III are novel compounds.
Compounds of formula V may be prepared from azlactones of formula VII by application of the Dakin-West reaction using either the acid chloride CICOCHgCHgCOgAlk or the corresponding 104 b* 3 j. 7 acid anhydride and employing triethylamine as the basic catalyst, as described hy W. Steglich and G. Hofle (Chem.
Ber. 1969, 102, 883 and Angew. Chem. Int. Ed. 1969, 8, 98l). This gives an intermediate azlactone of formula VIII which is hydrolysed hy heating in water to yield the γ-keto ester V. The corresponding γ-keto acid VI is obtained hy hydrolysis of the ester V by means of aqueous 8$ sodium bicarbonate solution The azlactone of formula VII may be prepared, optionally in situ, from the acyl α-amino acid of formula IX by conventional methods, for example reaction with dicyclohexylcarbodiimide, or reaction with an acid anhydride such as acetic anhydride, or an acid chloride conveniently the 3-chloroformylpropionic acid ester ClCOCHgCB^COgAlk referred to above.
T3 HOOCCHNHCORg (IX) For administration, the compounds of Formula I and salts thereof may be formulated in association with a non-toxic physiologically acceptable carrier or diluent, and with or without supplementary medicinal agents. -114 6 317 The invention-also provides pharmaceutical compositions which are characterised in that they contain a compound of formula I or a non-toxic physiologically acceptable salt thereof, preferably in association with a physiologically acceptable carrier or diluent. The compositions may include, for example, solid or liquid preparations for oral use, or may be in the form of suppositories, injections or in a form suitable for administration by inhalation.
Oral presentations are most conveniently in the form of tablets which may be prepared according to conventional methods, and may be coated if required. Soluble tablets suitable for sublingual administration may also be used.
Injections may be formulated with the aid of physiologically acceptable carriers and agents as solutions, suspensions or as dry products for reconstitution before use.
For administration by inhalation the compositions according to the invention can be in the form of a metered dose inhalation aerosol, a solution or suspension suitable for nebulisation by mechanical means, or as a cartridge from which the powdered composition may be inhaled with the aid of a suitable device.
The dosage at which the active ingredients are administered may vary within a wide range. A suitable per diem dos>age range for systemic use is generally from 0.1 to 100 mg. The pharmaceutical compositions may with advantage be formulated to -124 6 J I 7 provide a dose within this range either as a single unit or a number of units.
In the use of an aerosol for bronchodilation the dosage unit may be determined by providing a metering valve in the aerosol pack so that it delivers a metered amount on use.
Such a metered amount may be of the order of 10-1000^ug.
The compounds according to the invention may be formulated in combination with compounds that have stimulant activity at β-adrenoreceptors, for example, salbutamol and isoprenaline or in combination with compounds which have phosphodiesterase inhibitory activity, for example theophylline. -134 6 317 The following Examples illustrate the invention. Examples 13, 14 and 15 illustrate the production of intermediates.
EXAMPLE 1 l-Methyl-5-propyiimidazo[l,5-b]pyridazin-6(5H)-one (a)(i) 5-ButyTamido-4-oxohexanoic acid, ethyl ester A solution of N-butyrylalanine (1.59 g) in dry THP (10 ml) and triethylamine (2.8 ml) was treated with 4-dimethylaminopyridine (0.1 g) and then ethyl 3-chloroformylpropionate (2.8 ml) was added dropwise with rapid stirring during 5 minutes. The temperature was allowed to rise freely and it reached a peak at 43° and then cooled slowly to room temperature. The brown suspension was stirred at room temperature for 6 hours and left overnight. The reaction was then diluted with ethyl acetate (30 ml) and water (25 ml). The layers were separated and the aqueous layer extracted with ethyl acetate (2 x 20 ml). The combined organic layers were washed with water (6 x 20 ml), dried (anhydrous magnesium sulphate) and concentrated to ca, 10 ml. The solution was then absorbed onto a column Of silica gel (65 g) and eluted with 1:1 ethyl aeetate:cyclohexane. The first 250 ml contained a mixture of impurities and were discarded. The next 5θ0 ml of eluent contained the pure product, 0.82 g.
In a similar manner was prepared (ii) 5-isovaleramido-4oxohexanoic acid, ethyl ester (4.45 g) m.p. 41-43° (from petroleum ether b.p. 30-40°) from N-isovalerylalanine (6.9 g). -14(iii) 5-benzamido-4-oxohexanoic acid, ethyl ester (18.1 g) m.p. 87-89’’ from N-henzoylalanine (17.3 g). Two recrystallisations from ethyl acetate-cyclohexane gave a sample m.p. 89°. (iv) 5-butyramido-4-oxoheptanoic acid, ethyl ester (48 g) b.p. 140-144°/0.1 mm from 2-hutyramidohutyric acid (43.3 g). (h)(i) 3-(1-Butyramidoethyl)-4,5-dihydro-pyridazin-(IH)-6-one Ethyl 5-hntyramido-4-oxohexanoate (0.24 g) was heated under reflux with hydrazine hydrate (0.06 ml) in ethanol (3 ml) for 30 minutes. The solvent was evaporated and the solid residue recrystallised directly from ethyl acetate, m.p. 148150°, 0.08 g.
In a similar manner was prepared (ii) 3-(l-isovaleramidoel,hyl)-4,5-dihydro-pyridazin-6(lH)-one (3.3 g) m.p. 176.5-178 (from ethyl acetate), from ethyl 5-isovaleramido-4-oxohexanoate (4.5 g). (iii) 3-(1-henzamidoethyl)-4,5-dihydro-pyridazin-6(lH)-one (0.9 g) m.p. 175-6° (from ethanol-ethyl acetate), from ethyl 5-henzamido-4-oxohexanoate (1.38 g). (iv) 3-(1-hutyramidopropyl)-4,5-dihydropyridazin-6(lH)-one (23.5 g) m.p. 120-122° (after trituration with isopropyl acetate), from 5-6utyramido-4-oxoheptanoic acid, ethyl ester (43 g). Reerystallisation from isopropyl .acetate raised the m.p. to 125°. (v) 3-butyramidomethyl~4,5-dihydropyriaazin-6(lH)-one (5.4 g), m.p. 131-133° (from ethyl acetate) from 5-6ntyramido-4-oxopentanoic acid, ethyl ester (13.1 g) (Example 13). -154631*? (vi) 3-(l-benzamido-2-methylpropyl)-4,5-dihydropyridazin-6(lH)one (9 g) m.p. 175-176° (from ethyl acetate) from 5-benzamido6-methyl-4-oxoheptanoie acid (9.2 g) (Example 14(ii)), (vii) 3-benzamidomethyl-4,5-dihydropyridazin-6(lH)-one (2.2 g) m.p. 365-167° (from ethyl acetate-cyclohexane) from 5-benzamido4-oxopentanoic acid, ethyl ester (3.5 g) (Example I4(i)). ( c) (i ) 3-(1-Butyramidoethyl)-pyridazin-6 (IH) -one A solution of the dihydropyridazine (1.05 g) in glacial acetic acid (10 ml) was warmed to 50° and bromine (0.88 g) was added dropwise with stirring. The reaction mixture was heated at 50 for 3 hours then the solvent was evaporated in vacuo.
The residue was basified with 8% sodium bicarbonate solution and the product extracted with ethyl acetate (5 x 20 ml), Evaporation of the solvent gave the title compound m.p. 158l6o°, 0.6 g. Two reerystallisations from ethyl acetate gave a sample m.p. 163-164°.
Tn a similar manner was prepared (ii) 3-(l-isovaleramidoethyl)-pyridazin-6(lH)-one (0.72 g) m.p. 176-178° (from ethyl acetate) from 3-0-isovaleramidoethyl)-4,5-dihydro-pyridazin6(lH)-one (0.9 g). (iii) 3-(l-benzamidoethyl)-pyridazin-6(lH)-one (2.32 g) m.p, I9O-I950 from 3-(l-benzamidoethyl)-4,5-dihydro-pyridazin-6(lH)one (2.45 g), Two reerystallisations from ethyl acetatecyclohexane gave a sample m.p, 197-9°, (iv) 3-(l-but.yramidopropyl)-pyridazin-6(lH)-one (9.13 g) m.p. -164 6 317 155-157 from 3-(l-butyramidopropyl)-4, 5-dihydropyridazin6(lH)-one (14.25 g). Recrystallisation from ethanol-ethyl acetate gave material m.p. 156-158°. (v) 3-butyramidomethylpyridazin-6(lH)-one m.p. 124° (from ethyl acetate) from 3-butyramidomethyl-4,5-dihydropyridazin6(lH)-one (0.98 g). (vi) 3-(l-benzamido-2-methylpropyl)pyridazin-6(lH)-one (2.5 g) m.p. 246-247°, (from isopropanol), from 3-(l-benzamido-2methylpropyl)-4,5-dihydro-pyridazin-6(lH)-one (2.73 g). (vii) 3-benzamidomethylpyridazin-6(lH)-one (0.38 g) m.p. 142-144° (from ethyl acetate-cyclohexane) from 3-benzamidomethyl-4,5-dihydropyridazin-6(lH)-one (0.46 g). (d)(i) l-Methyl-3-propylimidazo[l,5-b]pyridazin-6(5H)-one 3-(l-Butyramidoethyl)-pyridazin-(lIl)-6-one (0.9 g) was heated at 120° for 2 hours in polyphosphoric acid (10 g).
The resultant solution was poured into water (20 ml) and hasified with solid sodium carbonate. The product was extracted with ethyl acetate (3 x 30 ml), the extracts were dried (anhydrous magnesium sulphate) and evaporated to give the title compound, 0.66 g, m.p. 155-157°. Two recrystallisations from ethyl acetate raised the m.p. to 158-160°.
In a similar manner was prepared (ii) 1-methyl-3-(2methylpropyl)lmidazo[l,5-b]pyridazin-6(5H)-one (1.55 g) m.p. 166-168° (from ethyl acetate/petroleum ether, b.p. 60-80°) from 3-(l-isovaleramidoethyl)-pyridazin-6(lH)-one (2.0 g). (iii) l-methyl-3-phenylimidazo[l,5-b]pyridazin-6(5H)-one (0.8 g) m.p. 230-232° from 3-(l-benzamidoethyl)-pyridazin-6(lH)-one (2 g). Recrystallisation from ethyl acetate raised the m.p. to 241-243°.
EXAMPLE 2 (i) 6-Chloro-l-methyl-3-propylimidazo[1,5-¾Jpyridazine, hydrochloride Procedure A A sample of l-methyl-3-propylimidazo [l,5-b]pyridazin6(5H)-one (2.7 g) was heated with phosphorus oxychloride (40 ml) under reflux for 6 hours. The reaction was then carefully poured onto ice-water (600 ml) and basified by the addition of sodium carbonate. The product was extracted into ethyl acetate (6 xlOO ml) and the combined extracts were washed with 2N sodium hydroxide solution (2 x 20 ml), water (2 x 20 ml) and finally dried over magnesium sulphate. Evaporation of the solvent gave a yellow-brown oil which was dissolved in ethyl acetate (20 ml) and ethereal hydrogen chloride added to give the hydrochloride salt of the title compound as a buff, amorphous powder, 1.8 g, m.p. 184-186°. Recrystallisation of the product from isopropanol/ethyl acetate gave a sample, m.p. 185-186°.
Procedure B 3-(l-Butyramidoethyl)-pyridazin-(lH)-6-one (42.75 g) was added in portions to phosphorus oxychloride (425 ml) with -184 6 317 stirring. Themixture was heated gently under reflux for 4 hours, cooled and then carefully added to ice-water (5 litres). The solution was hasified with potassium carbonate and extracted with ethyl acetate until the extracts were colourless (7 x 400 ml). The solution was then filtered through silica gel (100 g) and the filtrates evaporated to dryness to give the product as a yellow solid, 29.75 g, m.p. 46.5-48°. A sample was converted into the hydrochloride salt, m.p. 185.6°.
In a similar manner was prepared (ii) 6-chloro-l-methyl3-(2-methylpropyl)imldazo[l,5-b]pyridazine (5.6 g), (the hydrochloride salt had m.p. 194-196° from ethanol-ethyl acetate), from 3-(l-isovaleramidoethyl)-pyridazin-6(lH)-one (7.75 g). (iii) 6-chloro-r3-propyIimidazo[l,5-6]pyridazine as a gum (1.3 g), from 3-butyramidomethylpyridazin-6(lH)-onc (5.7 g). (iv) 6-ehioro-l-ethyl-3-propylimidazo[l,5-b]pyridazine (0.87 g), b.p. 110°/0.1 mm, from 3-(l-butyramidopropyl)-pyridazin-6(lH)one (2 g). (v) 6-chloro-3-phenylimidazo[l,3-b]pyridazine (0.43 g), m.p. 113-114° (from cyclohexane) from 3-benzamidomethylpyridazin6(lH)-one (0.6 g). (vi) 6-ehloro-l-isopropyl-3-propylimidazo[l,5-b]pyridazine as a yellow oil (3.9 g) (the hydrochloride salt had m.p. 102-104°), from 3-(l-butyramido-2-methylpropyl)-pyridazin-6 (lH)-one (4.6 g) (Example 15). -1946317 EXAMPLE 5 (i) 6-Amino-l-methyl-3-propylimidazo[l,5-b]pyridazine, hydrochloride 6-Chloro-l-methyl-3-propylimidazo[l,5~b]pyridazine (1.3 g) was heated with a saturated solution of dry ammonia in absolute ethanol (40 ml) in a closed pressure vessel at 180° for 4 days. Diatomaceous earth (15 g) was added and the mixture was evaporated to dryness. The residue was then added to the top of a column of silica gel (150 g). The column was eluted with ethyl acetate. The first 1000 ml contained starting material. The next 2000 ml contained the required product, 0.41 g. The product was dissolved in ethyl acetate (40 ml) and ethereal hydrogen chloride added until the yellow colour disappeared.
The precipitated salt was filtered and recrystallised directly from a mixture of ethanol and ethyl acetate to give a sample m.p. 264° (decomp.). (ii) In a similar manner 6-chloro-l-methyl-3~(2-methylpropyl) imidazo[l,5-b]pyridazine, hydrochloride (4.4 g) was converted into 6-amino-l-methyl-3-(2-methylpropyl)imidazo[l,5-b]pyridazine (1.33 g) (the hydrochloride salt had. m.p. 151-153° from ethyl acetate?-ethanol).
EXAMPLE 4 (i) l-Methyl-6-methylamino-5-propylimidazo[l,5-b]pyridazine, maleate 6-Chloro-l-raethyl-3-propylimidazo[l,5-b]pyridazine (2.1 g) -204 6 y χ 7 was heated in a closed pressure vessel with a solution of methylamine in ethanol (l6 ml, w/w) at 150° for 3 days.
The reaction mixture was then evaporated to dryness and the semi-solid residue diluted with water. The mixture was extracted with ethyl acetate (3 x 40 ml) and the organic extracts washed with 2N sodium hydroxide solution (2 x 10 ml), water (2 x 10 ml) and finally dried over anhydrous sodium sulphate. Evaporation of the solvent gave a pale yellow solid, l. 95 g. The product was dissolved in hot ethyl acetate (50 ml) and a solution of maleic acid (2.5 g) in hot ethyl acetate (25 ml) was added. The maleate salt crystallised on cooling (2.9 g) m.p. 121-123° (from ethyl acetate).
A sample of the free base, isolated from another similar experiment prior to the maleic acid treatment, had m.p. 138139.5°. (ii) In a similar manner 6-chloro-l-methyl-3-(2-methylpropyl) imidazo[l,5-bJpyridazine (1.5 g) was converted into 1-methyl6-methylamino-3-(2-methylpropyl)imidazo[l,5-bjpyridazine, hydrochloride (l.3 g) m.p. 247-249° (decomp.), (from ethyl acetate-ethanol). (iii) In a similar manner 6-chloro-l-methyl-3-propyi-imidazo [l,5-b]pyridazine (1.0 g) was converted into 6-ethylamino-lmethyl-3-propylimidazo[l,5-b]pyridazine, hydrochloride (0.63 g) m. p. 208.5-211° (from ethyl acetate-ethanol). (iv) In a similar manner 6-chloro-l-methyl-3-propylimidazo-21463151 fl,5-b]pyridazine (1.31 g) was converted into l-methyl-6-(lmethylethyl)amino-3-propylimidazofl,5-b]pyridazine, hydrochloride (0.64 g) m.p. 214-219.5° (from ethyl acetate-ethanol), (v) In a similar manner was prepared 6-methylamino-5-propylimidazofl,5-b]pyridazine (0.95 g) m.p. 112-115° (the hydrochloride salt had. m.p. 119-122° from isopropanol-ethyl acetate), from 6-ehloro-3-propylimidazo[l,5-b]pyridazine (l»3 g). (vi) In a similar manner was prepared 6-methylamino-lisopropyl-3-propylimidazo[l,5-b]pyridazine (1.7 g) m.p. 159161°, from 6-ehloro-l-isopropyl-3-propylimidazo fl,5-b jpyridazine (2.0 g). Recrystallisation from cyclohexane gave material m.p. 159.5-161.5°.
EXAMPLE 5 6-Dimethylamino-l-methyl-3-propyli!nidazofl,5-b]pyridazine, dimaleate 6-Chloro-l-methyl-3-propylimidazofl,5-b]pyridazine (2.1 g) and a solution of dimethylamine in ethanol (16 ml, 33% w/w) were heated together in a closed pressure vessel at 150° for 18 hours. The mixture was then evaporated to dryness and the residue diluted with water and extracted with ethyl acetate (3 x 50 ml). The organic extracts were washed with 2N sodium hydroxide solution (3 x 10 ml), water (2 x 10 ml) and finally dried (anhydrous sodium sulphate). Evaporation of the solvent gave an amber gum, 2.0 g. The gum was dissolved in ethyl acetate (20 ml) and a solution of maleic acid (2 g) in ethyl -2246317 acetate (25 ml) added. Addition of petroleum ether, b.p. 60-80° (25 ml) gave an oil which solidified on trituration in ether. The solid (2.6 g) was recrystallised from ethyl acetate to give a sample m.p. 85-87°.
EXAMPLE 6 l-Methyl-6-piperidino-3-propylimidazo[l,5-¾ jpyridazine, hydrochloride 6-Chloro-l-methyl-3-propylimidazo[l,5~b]pyridazine (1.5 g) was heated at 140° in a closed pressure vessel with piperidine (40 ml) for 24 hours. The pressure vessel was rinsed out with ethanol and the solvents evaporated. The residue was dissolved in ethyl acetate (100 ml) and the organic solution was washed with 2N sodium hydroxide solution (3 x 20 ml), water (30 ml) and finally dried (anhydrous magnesium sulphate). It was then filtered through a column of silica gel (25 g) and the yellow filtrate concentrated to 5 ml. Excess ethereal hydrogen chloride was then added, followed by petroleum ether b.p. 60-80° (50 ml) to give the product as a buff powder, 1.7 6, m.p. 186° (from ethyl acetate-petroleum ether, b.p. 60-80°). EXAMPLE 7 (i) l-Methyl-3-propylimidazo[l,5-b]pyridazine, hydrochloride 6-Chloro-l-methyl-3-propylimidazo[l,5-b]pyridazine (1.5 g) was hydrogenated over 10$ palladium on charcoal in ethyl acetate (100 ml) containing triethylamine (2 ml). The reaction absorbed 180 ml hydrogen (theoretical 172 ml) during 25 minutes. The -234 6 317 catalyst was filtered and washed with ethanol (3 x 20 ml).
The filtrate was evaporated to dryness and anhydrous ether added. The precipitated triethylamine hydrochloride was filtered off and the filtrate was evaporated to give a gum.
This was dissolved in ethyl acetate (50 ml) and the solution washed with 2N sodium hydroxide solution (3 x 15 ml), water (20 ml) and dried (anhydrous magnesium sulphate). The ethyl acetate solution was filtered through a column of silica gel (15 g) and the filtrate was treated with excess ethereal hydrogen chloride. The salt was filtered off and recrystallised from ethyl acetate containing a few drops of ethanol, 0.93 g, m.p. 137°. (ii) In a similar manner was prepared l-ethyl-3-propylimidazo [l,5-hjpyridazine (2.6 g), b.p. 90°/0.02 mm, from 6-ehloro-lethyl-3-propylimidazo[l,5-bjpyridazine (3.6 g).
EXAMPLE 8 6-Methoxy-l-methyl-5-propylimidazo[l,5-b jpyridazine, maleate 6-Chloro-l-methyl-3-propylimidazo[l,5-bjpyridazine (2.1 g) was heated in a closed pressure vessel at 150° for 18 hours with a solution of sodium (0.6 g) in methanol (15 ml). The reaction mixture was evaporated to dryness, water (30 ml) was added and the mixture extracted with ethyl acetate (3 x 40 ml). The combined organic extracts were washed with 2N sodium hydroxide solution (3 x 20 ml), water (2 x 20 ml) and finally dried (anhydrous sodium sulphate). Evaporation of the solvent -244631 gave an amber gum, 0.35 g. The gum was dissolved in ethyl acetate (10 ml) and added to a solution of maleic acid (0.5 g) in ethyl acetate (10 ml). The crystalline salt which separated was filtered off and washed with ethyl acetate to give the product, 0.33 g, m.p. 132-133°.
EXAMPLE 9 N-(l-Methyl-3-propylimidazo fl,5-¾]pyridazin-6-yl)acetamide A solution of 6-amino-l-methyl-3-propylimidazo[1,5-bjpyridazine, hydrochloride (0.148 g) in acetic anhydride (1 ml) and glacial acetic acid (0.5 mi) was heated on a steam bath for 24 hours. The solvent was evaporated and the residue recrystallised from ethyl acetate-ethanol to give the acetamide m.p. 233-236°.
EXAMPLE 10 6-Hydrazino-l-methyl-3-propyllmidazo|l,5-b jpyridazine dihydrochloride 6-Chloro-l-methyl-3-propylimidazo[l,5-b]pyridazine, (2.1 g) was heated with hydrazine hydrate (15 ml) in ethanol (40 ml) under reflux on the steam bath for 22 hr. The solvents were then evaporated, the residue dissolved in ethyl acetate (200 ml) and the solution washed with 2N sodium hydroxide solution (3 x 20 ml), water (2 x 20 ml), dried (anhydrous magnesium sulphate) and finally filtered through silica gel (30 g). The filtrate was concentrated to ca. 50 ml and ethereal hydrogen chloride added to give the dihydrochloride salt m.p. 258-260°, -2546317 2.05 g. Two recrystallisations from ethanol/ethyl acetate gave an. analytical sample m.p. 260-262°.
EXAMPLE 11 (i) l,6-Dlmethyl-5-propylimiaazo [T, 5-b jpyridazine’, hydrochloride (a) 5,6-Pihydro-l,6-dimethyl-5-propylimidazo[l,5-b jpyridazine A solution of l-methyl-3-propylimidazo[l,5-bjpyridazine (0.7 g) in dry ether was stirred under nitrogen, cooled to -20° and treated with a solution of methyl lithium in ether (2M, 2.25 ml). The reaction was stirred at -20° for 30 minutes then allowed to warm to room temperature, stirred for a further 2 hours then left overnight.
The reaction mixture was decomposed by the addition of isopropanol (2 ml) then the mixture partitioned between water (15 ml) and ethyl acetate (25 ml). The layers were separated and the aq. layer extracted with ethyl acetate (2 x 10 ml). The combined organic layers were washed with water (10 ml), dried (anhydrous magnesium sulphate), concentrated to ca. 10 ml and the solution absorbed onto a 1 column of silica gel (55 g). The column was eluted with ethyl acetate. The first 500 ml contained starting material. The next 800 ml contained the required product (0.62 g). (b) 1,6-Dimethyl-3-propylimidazo fl,5-b jpyridazine, hydrochloride The dihydro compound (0.6 g) was heated under reflux with 10°/ palladium on charcoal (0.5 g) in p-cymene (50 ml) for 2 hours with stirring. The reaction was then filtered through -2646317 diatomaceous earth, the solids washed with ethyl acetate until colourless and the filtrate stirred with 2N hydrochloric acid (50 ml). The layers were separated and the aq. layer washed with ethyl acetate. The aq. layer was hasified with potassium carbonate and extracted with ethyl acetate (3 x 50 ml). The extracts were combined, washed with water, dried (anhydrous magnesium sulphate) and the solvent evaporated to leave a yellow oil. The oil was dissolved in ethyl acetate (20 ml) and ethereal hydrogen chloride added, to give the title compound m.p. 160-2°, 0.44 g. Two recrystallisations from ethyl acetate plus a trace of ethanol gave an analytical sample, m.p. 161-3°. (ii) In a similar manner was prepared b-ethyl-l-methyl-3propylimidazo[l,5-b]pyridazine (1.02 g), (the hydrochloride salt had m.p. 148-150° from ethanol-ether) from l-methyl-3propylimidazo[l,5-b]pyridazine (1.75 g) via 5,6-dihydro-6ethyl-l-methyl-3-propylimidazo[l,5-b]pyridazine. (iii) In a similar manner was prepared 6-phenyl-l-methyl-3propylimidazo[l,5-b]pyridazine (0.58 g), m.p. 82-86° (the hydrochloride had m.p. 207-209°), from l-methyl-3-propylimidazo[l,5-b]pyridazine (0.77 g).
EXAMPLE 12 l-Methyl-3,6-dipropyIimidazo fl,5-bjpyridazine (a) 5,6-Dihydro-l-methyl-3,6-dipropylimidazo[l,5-h1pyridazine Following a similar method'to that of Example 11(a), the -2746317 title compound (4.2 g) was obtained as an oil from 1-methyl3- propylimidazo[l,5-b jpyridazine (3.5 g). (b) 6-Propyl-l-methyl-3-propylimidazo[l,5-b]pyridazine A solution of 5,6-dihydro-6-propyl-l-methyl-3-propylimidazo[l,5-b]pyridazine (4.2 g), potassium ferricyanide (15.08 g) and sodium bicarbonate (4.08 g) in water (150 ml) and acetone (100 ml) was heated under reflux for 19 hours.
An additional quantity of potassium ferricyanide (6.2 g) and sodium bicarbonate (1.63 g) were added and refluxing was continued for 6 hours. The solution was cooled and extracted with ethyl acetate. Removal of the solvent gave 6-propyl-lmethyl-3-propylimidazo[l,5-b]pyridazine (3.05 g), b.p. 135°/ x 10 mm Hg.
Intermediates EXAMPLE 15 -Butyramido-4-oxopentanoic acid, ethyl ester A solution of N-butyrylglycine (29 g) and dicyclohexylcarbodiimide (41.2 g) in methylene chloride (200 ml) was stirred for 16 hours. Dicyclohexylurea was removed by filtration and washed with methylene chloride (50 ml) which was combined with the filtrate. Triethylamine (28 ml) and 4- dimethylaminopyridine (0.5 g) were added and the solution cooled to 5° was treated with 3-chloroformyl propionic acid, ethyl ester (28 ml) added dropwise over 30 minutes. The mixture was stirred at 5° ior 30 minutes then at room temperature for -284 6 31 'Ζ hours. Water (50 ml) was added and the organic layer was separated, concentrated to dryness at 35° and the residue stirred vigorously with water (100 ml) for 18 hours. The mixture was extracted with ethyl acetate (3 x 100 ml) and the extracts were washed with 8$ sodium bicarbonate (50 ml) and dried (magnesium sulphate). The solvent was removed and the residue (57 g) was chromatographed on a column of silica gel (470 g). Elution with ethyl acetate-cyclohexane (1:1, 2.4 litres) gave a mixture of non-ketonic products, but further elution with ethyl acetate-cyclohexane (1:1, 4.8 litres) afforded the y-keto ester, 13.1 g.
EXAMPLE 14 (i) 5-Benzamido-4-oxopentanoic acid, ethyl ester A solution of 2-phenyl-5-oxazolone (l.6l g), triethylamine (1.4 ml) and 4-dimethylaminopyridine (0.1 g) in tetrahydrofuran (20 ml) was treated with ethyl-3-chloroformyl propionic acid, ethyl ester (1.4 ml) and stirred for 1 hour. The mixture was concentrated to dryness, treated with water (20 ml) and heated on a steam bath for 1 hour. The mixture was extracted with ethyl acetate (3 x 30 ml) and the extracts washed with 8$ sodium bicarbonate (5 x 25 ml), water (75 ml) and dried (magnesium sulphate). Removal of the solvent gave an oil which was chromatographed on a column of silica gel (45 g). Elution with ethyl acetate-cyclohexane afforded the y-keto ester (0.65 g) m.p. 98-100°. -294 6 317 (ii) In a similar manner 4-isopropyl-2-phenyl-5-oxazolone (101.5 g) was converted into 5-benzamido-6-methyl-4-oxoheptanoie acid (22.2 g), m.p. 126-128° (from ethanol-cyclohexane) by heating the crude ethyl ester with 8% aquaous bic&rbonate in ethanol.
EXAMPLE 15 -(l-Butyramido-2-methylpropyl)-pyridazin-6(lH)-one (a) 5-(l-Amino-2-methylpropyl)pyridazin-6(IH)-one, hydrochloride 3-(l-Benzamido-2-methylpropyl)pyridazin-6(lH)-one (Example lc(vi)) (10 g) in cone, hydrochloric acid (100 ml) was heated under reflux for 14 hours. The mixture was cooled and henzoic acid removed by filtration. The filtrate was evaporated to dryness and triturated with anhydrous ether to give the amine hydrochloride as a grey powder (7.2 g) m.p. 274-276° (from ethanol-ethyl acetate). (b) 5-(l-Butyramido-2-methylpropyl)pyridazin-6(IH)-one 3-(l-Amino-2-methylpropyl)pyridazin-6(IH)-one, hydrochloride (7.1 g) was dissolved in pyridine (100 ml). Triethylamine (3.5 ml) and butyric anhydride (6.1 g) were added and the mixture was stirred for 3i hours. The mixture was evaporated to dryness and the residue partitioned between ethyl acetate and water. The organic layer was washed with water (25 ml) and dried. Removal of the solvent gave the butyramide as a solid (5.6 g), m.p. 160-161° (from ethyl acetate-cyclohexane). -30Pharmaceutical Compositions Example 16 To prepare 10,000 tablets each containing 1 mg active ingredient Mix together 10 g powdered active ingredient, 500 g anhydrous lactose, 988.5 g microcrystalline cellulose and 1.5 g magnesium stearate. Compress on a suitable tablet machine using 8 nun diameter punches to produce tablets weighing about 150 mg.
Tablets of other strengths of active ingredient may be prepared by substituting the active ingredient for some of the anhydrous lactose.
The tablets may be film coated with suitable film forming material such as methyl cellulose, hydroxypropyl methyl cellulose or mixtures of these materials using standard techniques. The tablets may also he sugar coated hy standard sugar coating techniques.
Example 17 To prepare 10,000 capsules each containing 10 mg active ingredient Mix together 100 g active ingredient and 1100 g microcrystalline cellulose and fill into No. 5 hard gelatin capsules so that each capsule contains about 120 mg of the mixture.
Examp1e 18 To prepare an injection containing f mg/nil active ingredient Dissolve 1 g active ingredient and 9 g sodium chloride in 950 ml water for injections. When solution is complete make -514 6 317 up to 1 litre with more water for injections. Filter and subdivide the solution into suitabla size ampoules (1 ml, ml or 10 ml), seal and sterilise by heating in an autoclave. EXAMPLE 19 To prepare a syrup containing 10mg/5ml active ingredient Dissolve 12.0 kg sucrose in 5 L. hot water, add 2 L. glycerin and allow to cool, dissolve 40 g active ingredient in the syrup, and a suitable quantity of preservative of approved colour and flavour. Subdivide into 150 ml screw capped bottles.
EXAMPLE 20 To prepare cartridges each containing 50/ug active ingredient for inhalation Mix together 0,5 g micronised active ingredient and 250 g 15 lactose in a suitable mixer and fill 25 mg into each of No. 3 hard gelatin capsules.
Claims (16)
1. CLAIMS:- 1. Imidazo[l,5-b]pyridazines of the general formula I: R, (I) and physiologically acceptable non-toxic salts thereof, in which Rp R,, and Rj which may be the same or different represent a straight or branched chain alkyl or alkenyl group, or an aryl or aralkyl group in which the aryl group or the aryl moiety of the aralkyl group may be substituted by one or more hydroxy, alkoxy, or halogen atoms; and in which either or both of Rj and Rj may additionally represent hydrogen atoms and in which Rj may further represent a halogen atom, or an alkoxy, hydroxy, alkylthio or thiol group or may represent a group R^RjN- in which R4 represents a hydrogen atom or an alkyl or alkenyl group and Rj represents a hydrogen atom or an amino group or an alkyl, alkenyl, aryl or aralkyl group, in which the aryl group or the aryl moiety of the aralkyl group may optionally be substituted with one or more hydroxy or alkoxy groups; and in which the group Rj may also represent an acyl function RgCO-, in which Rg is a hydrogen atom or an alkyl or an aryl group; and in which the groups R^ and Rj may together with the adjacent nitrogen atom form a saturated 4 to 8 membered hetero 33 46317 cyclic ring which can contain an additional heteroatom and may he substituted.
2. Compounds as claimed in claim 1 in which the groups indicated below have the meanings given 5 Rj : hydrogen, alkyl, halo, alkoxy, hydroxy, aryl; or a group -NR^R^, in which R^ is hydrogen or alkyl and R^ is hydrogen, amino or alkyl; or an acyl function RgCO in which Rg is alkyl; or the group NR^Rj which represents a five or six-membered 10 heterocyclic ring; R 2 : alkyl or aryl R^ ; hydrogen or alkyl.
3. Compounds as claimed in claim 1 in which R^ represents hydrogen, alkyl, alkoxy, aryl, or a group -NR^R^ in which R^ 15 is hydrogen or alkyl and R e is hydrogen, eunino, alkyl or R,CO b b where R g is alkyl, or NR^R g represents piperidino.
4. Compounds as claimed in claim 2 in which the groups indicated below have the meanings given Rj hydrogen, methyl, ethyl, n-propyl, methoxy, phenyl, 20 or a group -NR^R^ in which R^ is hydrogen or methyl and Rj is hydrogen, amino, methyl, ethyl or isopropyl, or a group RgCO in which Rg is methyl, or NR^R^ is piperidino, R 2 : propyl,'isobutyl or phenyl, 25 R3 ; hydrogen, methyl, ethyl or isopropyl. 4 6 3 i
5. The compound as claimed in claim 1 which is selected from l-methyl-6-methylamino-3-propylimidazo [1,5-b]pyridazine and its salts.
6. The compound as claimed in claim 1 which is selected from 6-ethyl-l-methyl-3-propylimidazo [l,5-b]pyridazine and its salts.
7. The compound as claimed in claim 1 which is selected from l-methyl-6-methylamino-3-(2-methylpropyl)imidazo [1,5-b] pyridazine and its salts.
8. Compounds as claimed in claim 1 the preparation of which is specifically described in Examples 1 to 12, other than those claimed in claims 5, 6, or 7.
9. A process for the preparation of compounds as claimed in claim 1 and physiologically acceptable non-toxic salts thereof, which comprises (a) for the production of compounds in which R.| represents hydroxy, cyclising a compound of the general formula II: in which R 2 and have the meanings given in claim 1 with a strong acid; or (b) for the production of compounds in which Rj represents halogen, reacting a compound of formula I in which R^ is hydroxy with a compound which replaces the hydroxy group by a halogen atom, if desired with subsequent displacement of one halogen atom by a different halogen atom? or (c) for the production of compounds in which R^ is halo reacting a compound of formula II with a halogen introducing 4631'? reagent whereby cyclisation and replacement of the hydroxy group at the R^ position with a halogen atom is effected simultaneously; or (d) for the production of compounds in which R^ represents 5 a group NR^R^ in which R^ and R^ have the meanings given in claim 1, except that R^ cannot represent RgCO, treating a compound of formula I in which R^ is chlorine with ammonia or an appropriate primary or secondary amine HNR^R^; or (e) for the production of compounds in which R^ represents 10 a group -NR^Rg in which R^ is an amino group, treatment of a compound of formula I in which R^ is chlorine with a hydrazine; or (f) for the preparation of compounds in which R^ represents a group -NR^Rj and R. is a group RgCO in which Rg has the meaning given in claim 1 acylating a compound in which is 15 amino with an acylating agent to introduce a group RgCO; or (g) for the production of compounds in which R^ is alkoxy reaction of a compound of formula I in which Rj is chloro with an appropriate alkoxide; or (h) for the production of compounds in which R 4 is hydrogen 20 catalytically hydrogenating a compound of formula I in which R^ is chloro; or (i) for the preparation of compounds in which R^ represents alkyl, alkenyl, aryl or aralkyl which may be^substituted as defined in claim 1 treating a compound of formula I in which R^ 25 is hydrogen with an appropriate organolithium compound - 36 4 6 3X7 to produce a 6-substituted 5,6-dihydro-imidazo[l,5-b]pyridazine which is then dehydrogenated or oxidised to produce the appropriate compound of formula I; or (j) for the preparation of compounds in which Rj represents thiol or alkylthio, reaction of the compound of formula I in which Rj represents chlorine with potassium hydrogen sulphide with if necessary subsequent alkylation; said reactions comprising one or more of the steps (a) to (j); the desired end product being isolated, if desired, as a physiologically acceptable salt.
10. A process as claimed in claim 9 substantially as herein described with reference to Examples 1-15.
11. Compounds as claimed in claim 1 when prepared by a process as claimed in claim 9 or claim 10.
12. Pharmaceutical compositions comprising a compound as claimed in claim 1 or claim 11 in association with a non-toxic physiologically acceptable carrier or diluent, said composition if desired also including supplementary medicinal agents.
13. Compositions as claimed in claim 12 adapted for oral use, or for use as suppositories, or for use by injection or for use by inhalation.
14.Compositions as claimed in claim 12 or claim 13 formulated to provide a dosage of active ingredient of from 0.1 to 100 mg, as a single unit or number of units.
15. A composition as claimed in claim 13 adapted for use by - 37 4 6 317 inhalation and dispensed from an aerosol pack providing a metered dose containing from 10-1000/ug of said active compound.
16. A method of relieving bronchospasm which comprises 5 administering to an animal other than a human suffering from such bronchospasm an effective amount of a compound as claimed in claim 1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB5289/77A GB1583911A (en) | 1977-02-09 | 1977-02-09 | Imidazopyridazines and their use as therapeutic agents |
Publications (2)
Publication Number | Publication Date |
---|---|
IE780186L IE780186L (en) | 1978-08-19 |
IE46317B1 true IE46317B1 (en) | 1983-05-04 |
Family
ID=9793329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE186/78A IE46317B1 (en) | 1977-02-09 | 1978-01-27 | Imidazopyridazines and their use as therapeutic agents |
Country Status (15)
Country | Link |
---|---|
JP (1) | JPS53101397A (en) |
AU (1) | AU515804B2 (en) |
BE (1) | BE863759A (en) |
DE (1) | DE2804909A1 (en) |
DK (1) | DK46078A (en) |
ES (2) | ES466795A1 (en) |
FI (1) | FI780350A (en) |
FR (1) | FR2380281A1 (en) |
GB (1) | GB1583911A (en) |
IE (1) | IE46317B1 (en) |
IT (1) | IT1155821B (en) |
NL (1) | NL7801469A (en) |
NZ (1) | NZ186370A (en) |
SE (1) | SE7801489L (en) |
ZA (1) | ZA78554B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2473522A1 (en) * | 1980-01-16 | 1981-07-17 | Synthelabo | NOVEL DIHYDRO-2,3 IMIDAZO (1,2-B) PYRIDAZINE SUBSTITUTED DERIVATIVES AND MEDICAMENTS, PARTICULARLY USEFUL AS ANTIDEPRESSANTS, CONTAINING THEM |
US4391807A (en) * | 1982-07-12 | 1983-07-05 | The Dow Chemical Company | 6-Substituted tetrahydroimidazo[2,1-a]phthalazines and use as bronchodilators |
US4391806A (en) * | 1982-07-12 | 1983-07-05 | The Dow Chemical Company | Substituted tetrahydropyridazino-(1,6-A)benzimidazoles and use as bronchodilators |
US4485106A (en) * | 1982-07-12 | 1984-11-27 | The Dow Chemical Company | Substituted tetrahydrotetrazolo[5,1-a]phthalazines |
GB8429694D0 (en) * | 1984-11-23 | 1985-01-03 | Glaxo Group Ltd | Chemical compounds |
JPH07107404B2 (en) * | 1991-04-22 | 1995-11-15 | 上西鉄工株式会社 | Cylinder device |
-
1977
- 1977-02-09 GB GB5289/77A patent/GB1583911A/en not_active Expired
-
1978
- 1978-01-27 IE IE186/78A patent/IE46317B1/en unknown
- 1978-01-30 ZA ZA00780554A patent/ZA78554B/en unknown
- 1978-01-31 DK DK46078A patent/DK46078A/en not_active Application Discontinuation
- 1978-02-01 NZ NZ186370A patent/NZ186370A/en unknown
- 1978-02-03 FI FI780350A patent/FI780350A/en not_active Application Discontinuation
- 1978-02-06 DE DE19782804909 patent/DE2804909A1/en not_active Withdrawn
- 1978-02-08 ES ES466795A patent/ES466795A1/en not_active Expired
- 1978-02-08 AU AU33122/78A patent/AU515804B2/en not_active Expired
- 1978-02-08 BE BE184997A patent/BE863759A/en unknown
- 1978-02-08 NL NL7801469A patent/NL7801469A/en not_active Application Discontinuation
- 1978-02-08 SE SE7801489A patent/SE7801489L/en unknown
- 1978-02-08 IT IT7847968A patent/IT1155821B/en active
- 1978-02-09 FR FR7803669A patent/FR2380281A1/en active Granted
- 1978-02-09 JP JP1403578A patent/JPS53101397A/en active Pending
- 1978-11-15 ES ES475120A patent/ES475120A1/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
FI780350A (en) | 1978-08-10 |
DE2804909A1 (en) | 1978-08-10 |
IT1155821B (en) | 1987-01-28 |
NL7801469A (en) | 1978-08-11 |
SE7801489L (en) | 1978-08-10 |
ES475120A1 (en) | 1979-05-16 |
ZA78554B (en) | 1978-12-27 |
DK46078A (en) | 1978-08-10 |
BE863759A (en) | 1978-08-08 |
AU515804B2 (en) | 1981-04-30 |
GB1583911A (en) | 1981-02-04 |
IT7847968A0 (en) | 1978-02-08 |
JPS53101397A (en) | 1978-09-04 |
FR2380281A1 (en) | 1978-09-08 |
IE780186L (en) | 1978-08-19 |
NZ186370A (en) | 1981-03-16 |
FR2380281B1 (en) | 1982-03-12 |
AU3312278A (en) | 1979-08-16 |
ES466795A1 (en) | 1979-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4278673A (en) | Pharmacologically active compounds | |
CA1254564A (en) | Quaternary 6,11-dihydro-dibenzo-[b,e]-thiepine-11- n-alkyl-norscopine ethers and processes for preparing them | |
EP0689536B1 (en) | Naphthalene derivatives | |
JPH062750B2 (en) | Pyridazinone, method for producing the same, and therapeutic agent for bronchial diseases containing the compound | |
TW515795B (en) | Arylalkanoylpyridazine compound having inhibitory activity of phosphodiesterase IV, pharmaceutical composition comprising same and process for producing same | |
US3917608A (en) | Substituted 6,7 dihydro-1-oxo N(1H-tetrazol-5-yl)-1H,5H-benzo{8 ij{9 quinolizine carboxamides | |
PH26127A (en) | N-(pyridinyl)-1H-indol-1-amines and a process for their preparation | |
NZ250907A (en) | 2-(indol-2-yl- or quinol-3-yl-carbonylamino)-4-aryl thiazoles and pharmaceutical compositions | |
JPS62116514A (en) | Treatment for lhrh disease and sympton | |
US4359474A (en) | 1-Phenyl-pyrazole derivatives as glucagon inhibitors | |
US4213984A (en) | 11-(Piperazino-acetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones and salts thereof | |
IE46317B1 (en) | Imidazopyridazines and their use as therapeutic agents | |
US3600390A (en) | Novel 5-phenyl imidazolidino(5,1-a)5h-quinazolines and process therefor | |
NZ210875A (en) | Azepinones and pharmaceutical compositions | |
JPS6152834B2 (en) | ||
US4628055A (en) | Method for treating allergic reactions and compositions therefore | |
DE2424811A1 (en) | NEW PYRIDOBENZODIAZEPINONE, THE METHOD OF MANUFACTURING THEIR PRODUCTS AND THE MEDICINAL PRODUCTS CONTAINING THESE | |
DE2724501A1 (en) | NEW, 11-POSITION SUBSTITUTED 5,11-DIHYDRO-6H-PYRIDO SQUARE CLAMP ON 2.3-B SQUARE CLAMP ON SQUARE CLAMP ON 1.4 SQUARE CLAMP ON BENZODIAZEPIN-6- ONE, METHOD FOR THEIR PRODUCTION AND THESE CONNECTIONS DRUG | |
KR840000705B1 (en) | Process for preparing pyrimidine derivatives | |
JPS6348872B2 (en) | ||
US3836658A (en) | Tri-substituted imidazoles in the treatment of gout | |
US4108994A (en) | 5-thiazole-methane-amines, and their use as antilipolytics | |
NZ195688A (en) | 1-(8-quinolyl)-2-pyrrolidinone and pharmaceutical compositions | |
US4287211A (en) | Derivatives of phenylethylamines, processes for their preparation and related pharmaceutical compositions | |
NZ200859A (en) | 9,10-dihydro-1h,4h-pyrazolo(4,3-e)pyrido(3,2-b)(1,4)diazepin-10-ones and compositions |